CRIPAK is a negative regulator of PAK1 that is upregulated by estrogen. The predicted 446-amino acid protein contains an N-terminal C4 zinc finger domain, followed by 12 C3H zinc finger domains. Northern blot analysis detected wide expression of CRIPAK, with highest levels in trachea, prostate, and adrenal gland. RT-PCR revealed CRIPAK expression in all cancer cell lines examined.
Confocal microscopy of transfected breast cancer cells showed that CRIPAK had a predominant cytoplasmic and membrane localization; in some areas, CRIPAK partially colocalized with PAK1.Mutational analysis defined the binding regions as amino acids 132 to 270 of PAK1 and amino acids 367 to 446 of CRIPAK.
Organism species: Homo sapiens (Human)
CATALOG NO. | PRODUCT NAME | APPLICATIONS | |
Proteins | n/a | Recombinant Cysteine Rich PAK1 Inhibitor (CRIPAK) | Recombinant Protein Customized Service Offer |
Antibodies | n/a | Monoclonal Antibody to Cysteine Rich PAK1 Inhibitor (CRIPAK) | Monoclonal Antibody Customized Service Offer |
n/a | Polyclonal Antibody to Cysteine Rich PAK1 Inhibitor (CRIPAK) | Polyclonal Antibody Customized Service Offer | |
Assay Kits | n/a | CLIA Kit for Cysteine Rich PAK1 Inhibitor (CRIPAK) | CLIA Kit Customized Service Offer |
n/a | ELISA Kit for Cysteine Rich PAK1 Inhibitor (CRIPAK) | ELISA Kit Customized Service Offer |
- "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
- "CRIPak, a novel endogenous Pak1 inhibitor."Oncogene 25:1311-1319(2006) [PubMed] [Europe PMC] [Abstract]